PCPro: a clinically accessible, circulating lipid biomarker signature for poor-prognosis metastatic prostate cancer
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Background: Using comprehensive plasma lipidomic profiling from men with metastatic castration-resistant prostate cancer (mCRPC), we have previously identified a poor-prognostic lipid profile associated with shorter overall survival (OS). In order to translate this biomarker into the clinic, these men must be identifiable via a clinically accessible, regulatory-compliant assay. Methods: A single regulatory-compliant liquid chromatography-mass spectrometry assay of candidate lipids was developed and tested on a mCRPC Discovery cohort of 105 men. Various risk-score Cox regression prognostic models of OS were built using the Discovery cohort. The model with the highest concordance index (PCPro) was chosen for validation and tested on an independent Validation cohort of 183 men. Results: PCPro, the lipid biomarker, contains Cer(d18:1/18:0), Cer(d18:1/24:0), Cer(d18:1/24:1), triglycerides and total cholesterol. Within the Discovery and Validation cohorts, men who were PCPro positive had significantly shorter OS compared to those who were PCPro negative (Discovery: median OS 12.0 months vs 24.2 months, hazard ratio (HR) 3.75 [95% confidence interval (CI) 2.29–6.15], p < 0.001, Validation: median OS 13.0 months vs 25.7 months, HR = 2.13 [95% CI 1.46–3.12], p < 0.001). Conclusions: We have developed PCPro, a lipid biomarker assay capable of prospectively identifying men with mCRPC with a poor prognosis. Prospective clinical trials are required to determine if men who are PCPro positive will benefit from therapeutic agents targeting lipid metabolism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455 · cited 1×
“However, prostate cancer cells also express the appropriate biosynthetic enzymes and may produce ceramides that are transported into the circulation [5, 10].”
BackgroundCalibration: the Achilles heel of predictive analytics
On behalf of Topic Group ‘Evaluating diagnostic tests and prediction models’ of the STRATOS initiative, Van Calster, B., McLernon, D. J., van Smeden, M., Wynants, L., & Steyerberg, E. W. (2019) · BMC Medicine · doi:10.1186/s12916-019-1466-7 · Cited by 2,650
Phases of Biomarker Development for Early Detection of Cancer
Pepe, M. S., Etzioni, R., Feng, Z., Potter, J. D., Thompson, M. L., Thornquist, M., Winget, M., & Yasui, Y. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.14.1054 · Cited by 1,686
Sphingolipid metabolism in cancer signalling and therapy
Ogretmen, B. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.96 · Cited by 1,207 · cited 4×
“Most circulating ceramides are derived from the liver [8] and are elevated in systemic in fl ammation [9].”
BackgroundInfluentialTumor Marker Utility Grading System: a Framework to Evaluate Clinical Utility of Tumor Markers
Hayes, D. F., Bast, R. C., Desch, C. E., Fritsche, H., Kemeny, N. E., Jessup, J. M., Locker, G. Y., Macdonald, J. S., Mennel, R. G., Norton, L., et al. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.20.1456 · Cited by 748
Huynh, K., Barlow, C. K., Jayawardana, K. S., Weir, J. M., Mellett, N. A., Cinel, M., Magliano, D. J., Shaw, J. E., Drew, B. G., & Meikle, P. J. (2019) · Cell Chemical Biology · doi:10.1016/j.chembiol.2018.10.008 · Cited by 364
Self-citationTarasov, K., Ekroos, K., Suoniemi, M., Kauhanen, D., Sylvänne, T., Hurme, R., Gouni-Berthold, I., Berthold, H. K., Kleber, M. E., Laaksonen, R., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2559 · Cited by 251
Sphingosine 1-Phosphate Lyase Deficiency Disrupts Lipid Homeostasis in Liver
Bektas, M., Allende, M. L., Lee, B. G., Chen, W., Amar, M. J., Remaley, A. T., Saba, J. D., & Proia, R. L. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.081489 · Cited by 198
Recommendations for good practice in MS-based lipidomics
Köfeler, H. C., Ahrends, R., Baker, E. S., Ekroos, K., Han, X., Hoffmann, N., Holčapek, M., Wenk, M. R., & Liebisch, G. (2021) · Journal of Lipid Research · doi:10.1016/j.jlr.2021.100138 · Cited by 192
Crawford, E. D., Higano, C. S., Shore, N. D., Hussain, M., & Petrylak, D. P. (2015) · Journal of Urology · doi:10.1016/j.juro.2015.06.106 · Cited by 190 · cited 1×
“Prostate cancer is the second most common cancer and fi fth highest cause of cancer death in men worldwide [1].”
BackgroundRecent Advances in the Management of Metastatic Prostate Cancer
Sayegh, N., Swami, U., & Agarwal, N. (2022) · JCO Oncology Practice · doi:10.1200/op.21.00206 · Cited by 142 · cited 1×
“…prostate cancer (mCRPC), including taxane chemotherapy, androgen receptor signalling inhibitors (ARSI), poly-ADP ribose polymerase (PARP) inhibitors and lutetium-177-prostate-speci fi c membrane antigen [2], men will either have intrinsic resistance or develop treatment resistance.”
BackgroundClinical lipidomics: realizing the potential of lipid profiling
Meikle, T. G., Huynh, K., Giles, C., & Meikle, P. J. (2021) · Journal of Lipid Research · doi:10.1016/j.jlr.2021.100127 · Cited by 135
Self-citationAssociation of ceramides in human plasma with risk factors of atherosclerosis
Ichi, I., Nakahara, K., Miyashita, Y., Hidaka, A., Kutsukake, S., Inoue, K., Maruyama, T., Miwa, Y., Harada‐Shiba, M., Tsushima, M., et al. (2006) · Lipids · doi:10.1007/s11745-006-5041-6 · Cited by 96
Lightle, S. A., Tosheva, R., Lee, A. S., Queen-Baker, J., Boyanovsky, B. B., Shedlofsky, S., & Nikolova‐Karakashian, M. (2003) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2003.08.031 · Cited by 87 · cited 1×
“Most circulating ceramides are derived from the liver [8] and are elevated in systemic in fl ammation [9].”
BackgroundLin, H., Mahon, K. L., Weir, J. M., Mundra, P. A., Spielman, C., Briscoe, K., Gurney, H., Mallesara, G., Marx, G., Stockler, M. R., et al. (2017) · International Journal of Cancer · doi:10.1002/ijc.30903 · Cited by 83
Self-citationNormanno, N., Apostolidis, K., Lorenzo, F. D., Beer, P. A., Henderson, R., Sullivan, R. J., Biankin, A. V., Horgan, D., & Lawler, M. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.08.002 · Cited by 83
Lipid mechanisms in hallmarks of cancer
Molendijk, J., Robinson, H., Djurić, Z., & Hill, M. M. C. (2019) · Molecular Omics · doi:10.1039/c9mo00128j · Cited by 71 · cited 1×
“The long-term control of mCRPC requires strategies targeting multiple hallmarks of cancer including neoplastic cells, tumour microenvironment, in fl ammation, genetics and systemic metabolic factors (including lipid metabolism) [3].”
BackgroundSterols and sphingolipids: Dynamic duo or partners in crime?
Gulati, S., Liu, Y., Munkacsi, A. B., Wilcox, L. J., & Sturley, S. L. (2010) · Progress in Lipid Research · doi:10.1016/j.plipres.2010.03.003 · Cited by 63
Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase
Lin, H., Mak, B., Yeung, N. K., Huynh, K., Meikle, T. G., Mellett, N. A., Kwan, E. M., Fettke, H., Tran, B., Davis, I. D., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103625 · Cited by 63
Self-citationCholesterol – the devil you know; ceramide – the devil you don’t
Tippetts, T. S., Holland, W. L., & Summers, S. A. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.10.001 · Cited by 58
Therapeutic potential of targeting sphingosine kinase 1 in prostate cancer
Pchejetski, D., Böhler, T., Stebbing, J., & Waxman, J. H. (2011) · Nature Reviews Urology · doi:10.1038/nrurol.2011.117 · Cited by 51
Schrecengost, R. S., Keller, S. N., Schiewer, M. J., Knudsen, K. E., & Smith, C. D. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0626 · Cited by 50
Lin, H., Huynh, K., Kohli, M., Tan, W. W., Azad, A., Yeung, N. K., Mahon, K. L., Mak, B., Sutherland, P. D., Shepherd, A., et al. (2021) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-021-00338-z · Cited by 36
Self-citationWilson, B. E., Armstrong, A. J., Bono, J. S. D., Sternberg, C. N., Ryan, C. J., Scher, H. I., Smith, M. R., Rathkopf, D. E., Logothetis, C. J., Chi, K. N., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.03.042 · Cited by 33
Joshua, A. M., Armstrong, A., Crumbaker, M., Scher, H. I., de Bono, J., Tombal, B., Hussain, M., Sternberg, C. N., Gillessen, S., Carles, J., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.04.005 · Cited by 28
Lin, H., Yeung, N. K., Hastings, J. F., Croucher, D. R., Huynh, K., Meikle, T. G., Mellett, N. A., Kwan, E. M., Davis, I. D., Tran, B., et al. (2021) · Cancers · doi:10.3390/cancers13194964 · Cited by 19
Self-citationTarassov, K., Ekroos, K., Suoniemi, M., Kauhanen, D., Sylvänne, T., Hurme, R., Gouni-Berthold, I., Berthold, H. K., Kleber, M. E., Laaksonen, R., et al. (2014) · Kölner Universitäts PublikationsServer (Universität zu Köln) · Cited by 15
Tumour marker development: Towards validation of clinically useful markers
Hayes, D. F. (2007) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(07)70026-5 · Cited by 2
Daniels, B. J., Luckett, T., Holliday, S., Liauw, W., Lovell, M. R., Phillips, J. L., Rowett, D. S., John, T. N., Tervonen, H. E., & Pearson, S. (2020) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13408 · Cited by 2
Tibshirani (1997) · doi:10.1002/(sici)1097-0258(19970228)16:4<385::aid-sim380>3.0.co;2-3 · cited 1×
“1-2) [14, 15].”
Research works printed but not linked: 1
- National Pathology Accreditation Advisory Council. Requirements for the Development and Use of In-House In Vitro Diagnostic Medical Devices (IVDs) (Fourth Edition 2018). Fourth ed. Australia: National Pathology Accreditation Advisory Council; 2018.
Cited by
Takanashi, Y., Kahyo, T., Sekihara, K., Kawase, A., Setou, M., & Funai, K. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02121-0 · Cited by 34
“[25, 32, 34, 44, 47, 50– 52, 58], of”
BackgroundInfluentialOmics-Mediated Treatment for Advanced Prostate Cancer: Moving Towards Precision Oncology
Fatima, Y., Jobre, K. N., Gómez‐Gómez, E., Małkiewicz, B., Vlahou, A., Mokou, M., Mischak, H., Frantzi, M., & Jankowski, V. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157475 · Cited by 11
“…by 31 March 2024, and the trial has since been listed as “Closed” on the ANZUP website, with no efficacy results having been released so far [85,86]. d18:1/18:0), Cer(d18:1/24:0), Cer(d18:1/24:1)] plus total triglycerides and total cholesterol, which stratifies poor prognosis in mCRPC [87].”
InfluentialCastration-resistant prostate cancer monitoring by cell-free circulating biomarkers
Chrenková, E., Študentová, H., Holá, K., Kahounová, Z., Hendrychová, R., Souček, K., & Bouchal, J. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1394292 · Cited by 7
Lin, H., Scheinberg, T., Portman, N., Kim, R., Mellor, R., Huynh, K., Faulkner, A. N., Mellett, N. A., Davis, I. D., Martin, A. J., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.05.529 · Cited by 5
Self-citationMellor, R., Ardolino, L., Scheinberg, T., Fitzpatrick, M., Lin, H., Bonnitcha, P., Sullivan, D., Meikle, P. J., Stockler, M. R., Moujaber, T., et al. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241307814 · Cited by 5
“PCPro-positive men with mCRPC have significantly shorter survival overall than those who are PCPro-negative (HR 3.75, 95% CI 2.29–6.15, p 0.001 in the discovery cohort and HR 2.13, 95%CI 1.46–3.12, p 0.001 in the validation cohort) 20 (Figure 1).”
InfluentialSelf-citation
Metadata
- Authors
- Scheinberg, T., Lin, H.-M., Fitzpatrick, M., Azad, A. A., Bonnitcha, P., Davies, A., Heller, G., Huynh, K., Mak, B., Mahon, K., Sullivan, D., Meikle, P. J., & Horvath, L. G.
- Affiliations
- The University of Sydney (AU)
- Garvan Institute of Medical Research (AU)
- Royal Prince Alfred Hospital (AU)
- The University of Melbourne (AU)
- Monash Health (AU)
- Baker Heart and Diabetes Institute (AU)
- Corresponding author
- Horvath, Lisa G.
- ORCID
- Venue
- Prostate Cancer and Prostatic Diseases
- Published
- 2023-05-05
- Volume
- 27
- Issue
- 1
- Pages
- 136-143
- ISSN
- 1365-7852 (ISSN-L)
- 1476-5608
- PMC
- PMC10876475
- OpenAlex
- W4372270897
- Cited by
- 15
- References
- 29
- Citations by year
- 2026: 6 · 2025: 4 · 2024: 4 · 2023: 1
- FWCI
- 1.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Prostate Cancer and Prostatic Diseases (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by)
- Funders
- Prostate Cancer Foundation
- Movember Foundation (MRTA-3)
- Australian Prostate Cancer Research
- Australian Government
- Prostate Cancer Foundation of Australia (MRTA3)
- Cancer Institute NSW (10/TPG/1‐04, 2018/TPG001, 10/TPG/1-04, 2018/TPG001)
- State Government of Victoria
- Astellas Pharma
- Australian and New Zealand Urogenital and Prostate Cancer Trials Group
- Medical Research Council
- National Health and Medical Research Council (2009965, 1197190, 1196225, 1098647)
- Cancer Council NSW (PG 10-01)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolomics and Mass Spectrometry Studies
- Keywords
- metastatic castration-resistant prostate cancer, plasma lipidomics, prognostic factors, overall survival, ceramide, triglycerides, cholesterol, lipid metabolism
- MeSH terms
- Humans, Lipids, Male, Prognosis, Prospective Studies, Biomarkers, Prostatic Neoplasms, Castration-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.